Discover cutting-edge studies on carcinogenesis, biomarkers, and targeted therapeutic approaches
Discover how BI 882370, a novel RAF kinase inhibitor with DFG-out binding mode, offers unprecedented precision in treating BRAF-mutant cancers without normal tissue hyperproliferation.